Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

Zydus Lifesciences on Saturday (September 26) said a US Food and Drug Administration (USFDA) inspection of its pharmacovigilance and post-marketing surveillance system at its New Jersey, US office concluded with nil observations.The inspection was conducted from September 22 to September 25, 2026…